Platelet-Rich Plasma (PRP) for Hair Loss

Platelet-rich plasma, commonly called PRP, is an autologous treatment prepared from a patient’s own blood. The blood is processed to concentrate platelets and plasma components, and the resulting preparation is injected into areas of the scalp affected by hair loss.

Among the treatments commonly grouped under regenerative medicine, PRP currently has one of the largest clinical evidence bases for hair loss, particularly for androgenetic alopecia in men and women. Randomized clinical trials and systematic reviews suggest that properly prepared PRP can increase hair density and improve certain hair growth measurements in some patients.

That does not mean every PRP treatment is equivalent or that every patient will respond.

PRP is not a standardized pharmaceutical product. Platelet concentration, total platelet dose, leukocyte and red blood cell content, preparation method, activation, injection volume, treatment interval and even the patient’s baseline blood characteristics can differ substantially from one protocol to another.

Those differences are among the central reasons PRP results can vary widely between studies and medical practices. They also make it difficult to determine whether a particular commercial PRP system will reproduce the results reported in clinical research.

What Is Platelet-Rich Plasma?

Platelets are small blood components best known for their role in clotting, but they also contain and release numerous proteins and signaling molecules involved in wound healing, tissue repair and cellular communication.

PRP is produced by drawing a patient’s blood and processing it, usually through centrifugation, to separate and concentrate platelets within a smaller volume of plasma.

The resulting preparation is collected and injected into areas of the scalp affected by hair thinning.

PRP used for hair loss is therefore not a manufactured stem cell product, exosome product or pharmaceutical drug. It is an autologous blood-derived preparation generally produced at or near the time of treatment.

Although PRP is frequently marketed as a regenerative treatment, that description should not be interpreted to mean that it can generate entirely new hair follicles or reverse every form of hair loss.

How Might PRP Affect Hair Follicles?

The exact mechanism through which PRP may improve hair growth remains incompletely established.

Platelets contain and release numerous signaling molecules, including platelet-derived growth factor, vascular endothelial growth factor, insulin-like growth factor and other mediators associated with tissue repair, vascular function and cellular activity.

Laboratory research suggests that PRP may influence dermal papilla cells, support blood vessel development around follicles and affect signaling pathways associated with the anagen, or active growth, phase of the hair cycle.

These findings provide a biologically plausible explanation for the improvements observed in some clinical trials.

However, identifying growth factors within a PRP preparation does not establish that a particular concentration, combination or preparation method will produce superior hair growth.

Laboratory evidence of biological activity should not be confused with proof of clinical effectiveness.

Can PRP Create New Hair Follicles?

There is no established clinical evidence that PRP creates a new population of fully functional human scalp hair follicles.

PRP appears to work, when it works, primarily by influencing existing viable follicles.

A miniaturized follicle affected by androgenetic alopecia is still present and may retain some capacity to produce a thicker or longer hair. Stimulating that follicle is fundamentally different from generating an entirely new follicular organ where none remains.

Claims that PRP can reliably regenerate completely bald scalp, restore follicles permanently destroyed by scarring or create unlimited new hair growth go beyond current clinical evidence.

PRP should not be confused with experimental hair follicle regeneration, cell multiplication or follicular cloning technologies.

How Strong Is the Evidence for Androgenetic Alopecia?

The evidence supporting PRP has grown considerably since it first became popular in hair restoration.

A comprehensive 2025 systematic review and meta-analysis identified 43 randomized controlled trials involving 1,877 participants across studies of alopecia. The review found favorable effects on several clinical outcomes, particularly hair density, although results differed according to preparation methods and study characteristics.

A separate 2024 systematic review focusing on male androgenetic alopecia included eight randomized controlled trials and one prospective cohort study. Most studies reported improvements in hair density or hair count, but the authors emphasized protocol heterogeneity, methodological limitations and the absence of standardized treatment approaches.

Other meta-analyses of randomized clinical trials have also reported improvements in hair density compared with placebo or control treatments.

These findings support the conclusion that PRP has genuine clinical activity in some patients with androgenetic alopecia.

However, the number of published trials should not be confused with uniform certainty across every outcome. Many studies remain relatively small, follow-up is often limited, and differences in platelet preparation, injection technique and treatment frequency complicate comparisons.

Some reviews also combine studies involving different forms of alopecia, meaning their overall participant totals do not necessarily represent evidence specifically applicable to androgenetic alopecia.

The appropriate conclusion is that PRP has credible clinical evidence of benefit for androgenetic alopecia, but the magnitude, durability and predictability of that benefit remain variable.

It is neither scientifically reasonable to dismiss PRP as an unsupported treatment nor appropriate to describe every commercial PRP protocol as clinically validated.

How Much Improvement Should Someone Expect?

There is no single reliable percentage of improvement that can be promised to every patient receiving PRP.

Clinical trials measure outcomes differently. Some report the number of hairs per square centimeter, some evaluate terminal hair counts, others examine hair shaft diameter, standardized photography, physician assessments or patient satisfaction.

Systematic reviews generally report average improvements in hair density, but individual responses range from little or no measurable benefit to improvements that may be cosmetically noticeable.

Importantly, a statistically significant increase in hair density is not necessarily equivalent to a dramatic cosmetic improvement.

A relatively small increase in the number of hairs within a measured scalp area may be scientifically meaningful without substantially changing a patient’s appearance.

Patients should also understand that study averages cannot reliably predict their individual response.

PRP should therefore not be marketed as a guaranteed regrowth treatment, a replacement for hair transplantation or a procedure capable of restoring advanced baldness to youthful density.

Does PRP Work for Women?

Yes. There is meaningful clinical evidence supporting PRP in appropriately selected women with hair loss, particularly those with female pattern hair loss.

A 2024 systematic review and meta-analysis included 21 randomized controlled trials involving 628 women. Across the included studies, PRP was associated with improvements in hair density and thickness, with generally mild and temporary adverse effects.

However, the review included different forms of female hair loss, and findings from one diagnosis should not automatically be applied to another.

Female hair loss requires careful evaluation because diffuse thinning can result from androgenetic alopecia, telogen effluvium, iron deficiency, endocrine abnormalities, medication effects, inflammatory scalp disease or combinations of these conditions.

A woman experiencing sudden shedding after illness, rapid weight loss, pregnancy, medication changes or another physiological stressor should not automatically be directed toward PRP.

Likewise, a woman with an inflammatory or scarring form of alopecia may require treatment aimed at controlling the underlying disease rather than stimulation of hair growth alone.

The diagnosis should come before the treatment recommendation.

Is PRP Better Than Minoxidil?

Current evidence does not establish that PRP is universally superior to topical minoxidil.

A 2026 systematic review and meta-analysis involving nine randomized trials and 451 participants compared PRP with topical minoxidil for androgenetic alopecia.

Major outcomes, including hair density and terminal hair counts, were broadly similar between treatment groups. Patient satisfaction and certain secondary outcomes favored PRP, but differences in study design and treatment protocols limited the certainty of some findings.

These results do not establish that PRP should replace minoxidil.

Topical minoxidil has decades of clinical use, relatively standardized commercial formulations and the convenience of home application. PRP requires professional preparation, repeated scalp injections and considerably greater expense.

Although minoxidil also requires ongoing treatment to maintain its benefits, its practical burden is very different from that of regularly scheduled PRP procedures.

Comparable clinical results do not necessarily represent comparable convenience, cost effectiveness or long-term value.

For many patients, these treatments may occupy different roles rather than functioning as direct substitutes.

Does PRP Work Better When Combined With Minoxidil?

Some randomized trials and meta-analyses suggest that combining PRP with topical minoxidil may provide greater improvement in hair density than minoxidil alone.

A 2024 systematic review and meta-analysis of five randomized controlled trials found statistically significant improvements in hair density with combined PRP and minoxidil treatment at several follow-up intervals.

However, the authors rated the certainty of evidence as low to very low because of small sample sizes, risk of bias, differences in PRP preparation and substantial heterogeneity between studies.

Other pooled analyses have also reported favorable findings for combination treatment.

These results suggest that PRP may provide additional benefit in selected patients already using minoxidil.

They do not establish that everyone taking minoxidil should add PRP, nor do they prove that combination treatment provides superior long-term outcomes or represents a cost-effective approach for every patient.

The distinction is important because more treatment is not necessarily better treatment.

Patients who begin several therapies simultaneously may also have difficulty determining which intervention is producing the benefit.

The AHLA favors a carefully considered treatment plan in which each therapy has a clearly defined purpose, measurable benefit and acceptable burden.

Does PRP Replace Finasteride or Dutasteride?

No.

PRP does not directly inhibit dihydrotestosterone, commonly called DHT, and has not been demonstrated to eliminate the underlying androgen sensitivity responsible for androgenetic alopecia.

A patient with progressive male pattern hair loss may experience an improvement in hair density following PRP while the biological process responsible for follicular miniaturization continues.

Finasteride and dutasteride reduce DHT through inhibition of the enzyme 5-alpha reductase. Minoxidil and PRP act through different biological pathways.

These treatments should not be described as interchangeable.

Whether PRP should be used alone or as an adjunct depends on the diagnosis, disease severity, age, medical history, treatment tolerance, patient preferences and long-term management strategy.

A temporary cosmetic improvement should not be mistaken for permanent stabilization of androgenetic alopecia.

What Does “Not All PRP Is Created Equal” Really Mean?

This is one of the most important issues in PRP treatment.

There is no single universally standardized PRP preparation or injection protocol for hair loss.

Two medical practices can both advertise PRP while administering preparations that differ substantially in:

• Platelet concentration
• Total number of platelets delivered
• Platelet recovery from the original blood sample
• Plasma volume
• Leukocyte concentration
• Red blood cell contamination
• Centrifugation method
• Number and speed of centrifuge cycles
• Activation method
• Anticoagulant used during preparation
• Injection depth
• Injection volume
• Injection spacing
• Treatment frequency

These variables can affect the biological composition of the final preparation and potentially influence treatment outcomes.

A positive clinical trial involving one preparation does not demonstrate that every commercial PRP system will produce the same result.

Similarly, the fact that a particular device concentrates platelets efficiently does not establish that it is clinically superior for hair restoration.

Patients should be skeptical of marketing that treats PRP as a single uniform procedure or implies that all systems produce equivalent biological products.

Is Platelet Concentration Important?

Probably, but the relationship is more complicated than simply assuming that more platelets produce better hair growth.

Some clinical studies have reported greater improvements in hair density or thickness with higher platelet concentrations.

A randomized, double-blind split-scalp study involving 80 patients found that platelet counts influenced certain hair growth outcomes. However, the findings do not establish a universally optimal platelet concentration.

Platelet concentration describes the number of platelets within a given volume of plasma.

Total platelet dose, on the other hand, considers both concentration and the volume delivered.

For example, a small volume of highly concentrated PRP may contain fewer total platelets than a larger volume of moderately concentrated PRP.

Another variable is platelet recovery, which describes how efficiently the preparation system captures platelets from the original whole-blood sample.

Even these measurements do not describe every biologically relevant characteristic of the preparation.

Platelet function, leukocyte content, red blood cell contamination, activation and patient-specific blood characteristics may also influence biological activity.

There is currently no universally validated platelet concentration or total platelet dose that guarantees optimal hair growth.

Claims that a system is superior simply because it produces PRP at a higher multiple of the patient’s baseline platelet concentration should therefore be interpreted cautiously.

Should a Clinic Measure the Platelet Count?

A medical practice performing PRP should understand the type of preparation its system produces.

Ideally, the treating physician should know the patient’s baseline platelet status when clinically relevant and understand the typical platelet concentration, recovery characteristics and final volume produced by the preparation system.

Unfortunately, many published PRP studies have inadequately reported these variables.

Earlier systematic reviews of PRP preparation methods found that only a minority of studies provided both baseline whole-blood platelet counts and final PRP platelet concentrations.

This incomplete reporting makes comparisons between studies and commercial preparation systems more difficult.

A physician does not necessarily need to perform laboratory testing on every PRP preparation to practice responsibly. Validated system characteristics and appropriate quality-control procedures may provide useful information.

However, a manufacturer’s advertised platelet concentration does not necessarily establish the exact platelet dose or composition received by every individual patient.

Patients should be able to ask what type of PRP is being administered and how the practice evaluates the consistency of its preparation method.

Simply stating that a system produces high-quality PRP is not an adequate scientific explanation.

Are Higher Growth Factor Levels Always Better?

That has not been established.

Growth factor concentrations vary with platelet biology, preparation methods, activation and other characteristics of the blood-derived product.

Although growth factors are central to the biological rationale for PRP, there is no validated clinical requirement that physicians measure individual growth factor concentrations before each hair-loss treatment.

There is also no established threshold demonstrating that a higher concentration of any particular growth factor reliably produces superior hair growth.

Different signaling molecules may have different biological effects, and their activity cannot be reduced to a single number.

Marketing claims based primarily on producing more growth factors should therefore be interpreted cautiously.

Higher concentrations do not automatically establish greater efficacy or better clinical outcomes.

Do Leukocytes Matter?

Possibly.

PRP preparations may contain relatively high or low concentrations of white blood cells, commonly described as leukocyte-rich or leukocyte-poor PRP.

These preparations are biologically different.

Leukocytes can release inflammatory mediators and enzymes, but they may also contribute signaling molecules involved in tissue repair and cellular responses.

Whether leukocyte-rich or leukocyte-poor PRP is consistently superior for androgenetic alopecia remains unresolved.

The available evidence does not justify a universal recommendation that all PRP used for hair restoration should contain either high or low leukocyte concentrations.

Patients should nevertheless understand that leukocyte content is a meaningful characteristic of a preparation and that two products marketed as PRP may differ substantially in this respect.

What About Red Blood Cells?

Most PRP preparation methods attempt to minimize red blood cell contamination.

Red blood cells are not the intended therapeutic component of PRP, and excessive contamination may contribute to local irritation, inflammatory responses or discomfort.

However, precise thresholds for red blood cell content that optimize hair-growth outcomes have not been established.

The important point is that platelet concentration alone does not adequately describe the final preparation.

The overall cellular composition matters.

Does PRP Need to Be Activated?

There is no universally accepted answer.

Some PRP preparations are activated before injection using substances such as calcium salts or thrombin to promote platelet activation and the release of growth factors.

Other protocols use nonactivated PRP and rely on platelet activation occurring after injection through contact with tissue components.

A 2025 comprehensive meta-analysis reported favorable findings for activated PRP, including improvement in hair density. An individual randomized split-scalp study also identified activation as a factor associated with improved outcomes.

However, some expert consensus recommendations favor administering PRP without routine external activation, and clinical studies using nonactivated PRP have also reported benefit.

These findings should not be interpreted as proving that all PRP preparations require artificial activation.

Activation is biologically relevant, but its clinical effects may depend on the preparation method, platelet concentration, injection protocol and other variables.

The available literature does not establish that activated PRP is universally superior or that nonactivated PRP is ineffective.

How Is PRP Treatment Performed?

A typical PRP treatment begins with a blood draw.

The collected blood is placed into a preparation system, generally using an anticoagulant when required by the protocol, and processed to separate and concentrate the platelet-containing plasma fraction.

The resulting preparation is collected and injected into areas of the scalp affected by hair thinning.

Injection techniques vary. Some physicians use multiple small injections at regular intervals, while others use different depths, volumes or treatment patterns.

Topical or local anesthetic may be used to improve comfort.

The procedure generally takes longer than a routine blood draw because of preparation and multiple scalp injections.

The person performing the injections should be appropriately qualified, and the procedure should take place under suitable medical oversight with appropriate infection-control practices.

Patients should understand who is responsible for diagnosis, preparation, treatment and management of potential complications.

How Many PRP Treatments Are Needed?

There is no universally established treatment schedule.

A commonly studied approach involves approximately three initial treatments spaced about one month apart, followed by reassessment.

Other studies use different treatment intervals, numbers of sessions and maintenance protocols.

Some clinical consensus recommendations suggest maintenance treatments every three to six months, but these schedules are not supported by evidence demonstrating that every patient requires ongoing injections at a particular interval.

The evidence supporting an initial treatment course is stronger than the evidence establishing the ideal long-term maintenance strategy.

Patients should not assume that monthly PRP injections must continue indefinitely.

The appropriate number of treatments should be based on the protocol being used, objective response, disease progression, patient preferences and the financial burden of treatment.

Does More Frequent PRP Treatment Produce Better Results?

Not necessarily.

Some protocols involve more frequent injections than others, but the available research does not establish that a greater number of treatments automatically produces superior hair growth.

Differences between study outcomes may reflect platelet preparation, total dose, injection technique, treatment frequency or other variables.

It is therefore difficult to isolate the effect of treatment frequency alone.

A patient should be cautious when a clinic suggests that purchasing a more intensive package will necessarily produce a better result.

More injections are not automatically better treatment.

How Long Does PRP Take to Work?

Hair growth is gradual, and changes in the hair cycle generally occur over months rather than days or weeks.

Clinical studies commonly evaluate results after several months of treatment.

Patients should not expect immediate cosmetic regrowth following an injection.

Standardized clinical photography, target-area hair counts and trichoscopic measurements can help determine whether treatment produces a measurable benefit.

Photographs should be obtained under reasonably consistent lighting, hair length, styling and positioning conditions.

Without reliable baseline documentation, it can be difficult to distinguish actual improvement from differences in photography, temporary changes in shedding or natural variations in appearance.

This is especially important when patients are paying substantial amounts for a series of procedures.

How Long Do PRP Results Last?

The long-term durability of PRP treatment remains incompletely established.

Androgenetic alopecia is a chronic, progressive condition.

Even when PRP produces measurable improvement, it has not been demonstrated to eliminate the underlying genetic and hormonal susceptibility of affected follicles.

Some patients receive periodic maintenance treatments in an effort to preserve their response.

However, high-quality evidence establishing the optimal maintenance schedule, the duration of benefit after stopping treatment or the effectiveness of PRP over many years remains limited.

There is no scientific basis for guaranteeing that a short course of PRP will permanently stabilize pattern hair loss.

Patients should be cautious when PRP is marketed as a permanent, one-time solution.

Can Someone Become Dependent on PRP?

PRP is not known to produce physiological dependence.

However, that does not mean any improvement will necessarily remain after treatment stops.

If PRP temporarily improves the activity of existing follicles, some of that benefit may diminish over time, particularly when the underlying androgenetic alopecia continues to progress.

There is insufficient evidence to establish a predictable pattern of hair loss following PRP discontinuation or to determine exactly how long benefits persist in every patient.

The need for additional treatment should be based on documented response and ongoing clinical assessment rather than an assumption that all patients require lifelong injections.

Who Is Most Likely to Benefit?

There is no validated clinical test that reliably predicts which patients will respond to PRP.

Biologically viable, miniaturized follicles are more plausible treatment targets than completely smooth areas of longstanding baldness where functioning follicles have been severely depleted.

Patients with earlier or moderate androgenetic alopecia may therefore have a more realistic opportunity for improvement than patients with extensive longstanding baldness.

However, age, duration of hair loss and clinical stage are not perfect predictors of response.

Individual PRP composition and other biological variables may also affect results.

A physician should not guarantee success based solely on a patient’s Norwood classification, Ludwig classification or apparent degree of thinning.

Realistic expectations and an accurate diagnosis are essential.

Does PRP Work on the Hairline or Crown?

PRP has been studied in androgenetic alopecia affecting different areas of the scalp.

When viable miniaturized follicles remain, some improvement may be possible.

However, there is no reliable evidence that PRP can reconstruct a severely receded frontal hairline or restore completely bald crown tissue in the way that hair transplantation can redistribute existing follicles.

PRP does not create new donor hair or replace follicles that have been permanently lost.

Patients with advanced frontal recession or substantial crown baldness should be particularly cautious about promises of dramatic regrowth.

What About Alopecia Areata?

PRP has also been investigated for alopecia areata, an autoimmune condition in which immune activity targets hair follicles.

Several small randomized trials have compared PRP with intralesional corticosteroids. Systematic reviews have generally not demonstrated a consistent statistically significant advantage for PRP over established injectable corticosteroid treatment.

The 2026 German S3 guideline for alopecia areata concluded that available evidence was insufficient to recommend either for or against PRP in adults.

Importantly, the guideline specifically recommends that PRP not be offered to children and adolescents with alopecia areata.

Contemporary British dermatology guidance has also found insufficient evidence to recommend PRP routinely for alopecia areata.

PRP should therefore be regarded as a treatment with insufficient evidence for routine recommendation in adult alopecia areata, rather than a replacement for established local or systemic therapies.

The effectiveness of a treatment in androgenetic alopecia does not establish that it will be effective for an autoimmune form of hair loss.

What About Scarring Alopecia?

The evidence supporting PRP for scarring alopecia is substantially weaker.

Small case reports and uncontrolled studies have investigated PRP in conditions such as lichen planopilaris and other cicatricial alopecias, sometimes reporting improvements in symptoms or inflammatory findings.

However, PRP has not been established as a treatment capable of reliably controlling active scarring alopecia or recreating follicles permanently destroyed by fibrosis.

Conditions such as lichen planopilaris and frontal fibrosing alopecia require accurate diagnosis and appropriate disease-directed management.

The priority in active scarring alopecia is preserving follicles that have not yet been irreversibly destroyed.

A treatment marketed as regenerative should never delay appropriate evaluation or established anti-inflammatory treatment when progressive follicular destruction is occurring.

Does PRP Treat Telogen Effluvium?

PRP is not an established treatment for ordinary telogen effluvium.

Telogen effluvium involves disruption of the normal hair cycle and may follow illness, surgery, rapid weight loss, nutritional deficiencies, medication changes, endocrine disturbances or other physiological stressors.

Treatment should focus on identifying and addressing the underlying cause when possible.

Some PRP studies have included participants with different forms of alopecia, but that does not establish PRP as a routine treatment for acute or chronic telogen effluvium.

It is also important to recognize that telogen effluvium may improve naturally over time.

A patient who begins PRP during a period of spontaneous recovery may incorrectly attribute that improvement to the injections.

This is another reason accurate diagnosis and objective documentation are important before initiating an expensive procedural treatment.

Can PRP Improve Hair Transplant Results?

Possibly, but the evidence remains limited.

A 2025 systematic review identified three controlled studies involving 217 hair transplantation patients. Some reported favorable outcomes associated with PRP, including increased hair density, earlier visible growth or improvements in measures described as graft survival.

However, these outcomes are not interchangeable.

Earlier visible growth, postoperative hair counts and actual graft survival represent different aspects of surgical recovery and success.

The available studies also used different PRP preparations, treatment methods and outcome measurements.

PRP may therefore be a reasonable adjunct in selected surgical practices, but it should not be presented as a requirement for successful hair transplantation.

It also cannot compensate for poor surgical planning, inappropriate donor harvesting, improper graft handling or inadequate patient selection.

The long-term success of hair transplantation depends primarily on appropriate candidacy, donor management, surgical technique and realistic planning for the future progression of hair loss.

PRP should never be used to justify otherwise questionable surgical decisions.

What Is Platelet-Rich Fibrin, or PRF?

Platelet-rich fibrin, commonly called PRF, is related to PRP but is not identical.

PRF preparations contain platelets within a fibrin-based structure and are produced using different processing protocols, often without the anticoagulants commonly used in PRP preparation.

Injectable PRF, sometimes called i-PRF, is a liquid preparation that can be injected before it forms a more organized fibrin network.

PRF is increasingly marketed as a next-generation or more natural alternative to PRP.

However, these descriptions do not establish clinical superiority.

A 2026 multicenter randomized clinical trial in women with female pattern hair loss compared PRP, injectable PRF and concentrated growth-factor preparations.

Seventy-four women completed the trial. All three treatments improved non-vellus hair counts within the measured target area.

At 24 weeks, the average percentage increase in target-area hair counts was approximately 14.5% with PRP, 26.5% with injectable PRF and 27.1% with concentrated growth factors.

These results suggest that certain alternative platelet concentrate preparations may provide greater short-term benefit than the specific PRP protocol used in that trial.

However, the findings do not establish that every commercial PRF or concentrated growth-factor system is superior to every PRP preparation.

The study evaluated specific protocols, and the findings require broader independent confirmation.

Long-term durability, optimal preparation methods and consistency across patient populations remain uncertain.

Is PRF the Same as PRP?

No.

PRP and PRF differ in preparation methods, fibrin architecture, cellular composition and the release patterns of platelet-derived signaling molecules.

Evidence supporting one preparation should not automatically be applied to the other.

The same principle applies to concentrated growth-factor systems and other autologous platelet concentrates.

The fact that a newer preparation produces different biological characteristics does not automatically mean it produces better clinical outcomes.

Patients should be cautious about terms such as advanced, next-generation, higher potency or superior regeneration when those claims are not supported by appropriate comparative clinical evidence.

Does Combining PRP With Microneedling Work Better?

Several clinical studies have investigated PRP combined with microneedling.

Some have reported favorable outcomes compared with individual interventions, but protocols vary substantially, and the evidence does not establish a universally superior combination approach.

Microneedling deliberately creates controlled injuries in the skin. Its proposed effects include local wound-healing responses and changes in cellular signaling.

Combining it with PRP introduces another variable, making it difficult to determine how much of the observed improvement comes from each component.

There is also an important regulatory distinction.

The FDA has not cleared microneedling devices for treating hair loss or for delivering blood products such as PRP into the skin.

FDA clearance of a microneedling device for another purpose does not establish the safety or effectiveness of PRP-assisted microneedling for hair loss.

The AHLA does not recommend unsupervised home microneedling combined with application of blood-derived regenerative preparations.

Any treatment involving deliberate disruption of the skin barrier and exposure to biological products requires careful consideration of contamination, infection and inflammatory risks.

Is PRP the Same as Stem Cell or Exosome Treatment?

No.

PRP is derived from the patient’s blood and contains concentrated platelets and associated plasma components.

It is not equivalent to a stem cell therapy, cultured follicular cell treatment or manufactured exosome product.

Although platelets release signaling molecules and extracellular vesicles, their presence does not establish that PRP can reproduce the effects claimed for other regenerative technologies.

Some commercial marketing blurs these distinctions by describing PRP as a treatment that activates stem cells or produces cellular regeneration.

Such claims require specific clinical evidence.

The presence of biologically active substances does not demonstrate that a treatment creates new follicles or permanently reverses hair loss.

PRP, platelet-rich fibrin, cellular therapies and exosome-based interventions should be evaluated as distinct approaches rather than treated as interchangeable forms of regenerative medicine.

Is PRP FDA Approved for Hair Loss?

There is no FDA-approved PRP drug or biological product specifically indicated for androgenetic alopecia or other forms of hair loss.

Certain devices used to separate blood components or prepare autologous platelet concentrates have received FDA clearance for specific intended uses.

For example, some systems have clearance associated with preparing platelet concentrates for use with bone graft materials or other defined applications.

That is not equivalent to FDA approval of PRP as a treatment for hair loss.

More importantly, the regulatory clearance of a preparation device does not establish that the particular PRP product it produces is clinically effective for androgenetic alopecia.

A clinic should not advertise PRP hair restoration as FDA approved merely because it uses an FDA-cleared centrifuge or blood-processing system.

Patients may reasonably ask for the device’s FDA clearance information and the specific intended uses covered by that clearance.

The difference between device clearance and approval of a particular medical treatment is fundamental.

What Are the Most Common Side Effects?

PRP is generally well tolerated in published hair-loss studies.

The most frequently reported adverse effects are local and temporary, including:

• Pain during scalp injections
• Scalp tenderness or soreness
• Redness
• Swelling
• Bruising
• Minor bleeding
• Headache or pressure sensations
• Temporary discomfort at injection sites

Some patients may also experience lightheadedness or fainting associated with blood collection or injections.

The 2025 comprehensive meta-analysis did not find a statistically significant overall increase in adverse-event rates compared with control treatments.

Serious complications appear uncommon in published hair-loss studies.

However, most studies are relatively small, and adverse-event collection and reporting are not always consistent.

A generally favorable short-term safety profile does not establish that every potential complication has been adequately evaluated or that rare adverse events can be reliably quantified.

Proper patient selection, sterile preparation and appropriate injection technique remain important.

Can PRP Cause Infection?

Yes, although infection appears uncommon when PRP is prepared and administered properly.

Blood collection, processing and scalp injections create potential opportunities for contamination if appropriate sterile procedures are not followed.

The use of a patient’s own blood reduces certain donor-related risks but does not eliminate the possibility of infection.

Patients should understand how their blood is processed, whether sterile and appropriately validated preparation equipment is used, and who performs the injections.

They should also know whom to contact if they develop increasing pain, spreading redness, significant swelling, fever, drainage or other concerning symptoms after treatment.

The word autologous should never be interpreted as meaning that a procedure is free of risk.

Who Should Avoid PRP or Receive Additional Medical Evaluation?

PRP is not appropriate for every patient.

Certain medical conditions may warrant postponing treatment, while others require individualized assessment.

Potential concerns include:

• Significant thrombocytopenia or a known platelet-function disorder
• Active infection or infection at the intended injection sites
• Significant anemia or unstable hematologic disease
• Active inflammatory scalp conditions requiring specific medical treatment
• Anticoagulant or antiplatelet medication use
• Serious uncontrolled systemic illness
• Active cancer or ongoing cancer treatment
• A history of significant reactions to blood draws or injection procedures

These considerations should not all be interpreted as absolute contraindications.

For example, an active infection at the planned treatment site generally warrants deferral, while a patient taking anticoagulant medication may require individualized evaluation of bleeding risk and the appropriateness of an elective procedure.

Patients receiving cancer treatment or living with serious hematologic disorders should be evaluated in consultation with the physicians managing those conditions.

There is insufficient evidence to make universal claims about PRP safety or effectiveness across all such populations.

What About Aspirin, NSAIDs or Blood Thinners?

Medications that affect platelet function or blood clotting may influence bleeding risk or the biological characteristics of a PRP preparation.

Some practices recommend avoiding nonsteroidal anti-inflammatory drugs, commonly called NSAIDs, around PRP treatment because these medications can affect platelet activity.

However, evidence establishing precisely how these drugs influence hair-growth outcomes after PRP is limited.

There is also no universally validated medication-withholding schedule specifically for hair-loss PRP.

Most importantly, patients should never independently stop prescribed aspirin, anticoagulants or antiplatelet medications simply to undergo PRP.

Stopping these medications can carry serious medical risks.

Any medication adjustment should be coordinated with the prescribing clinician and the physician responsible for the procedure.

What About Pregnancy and Breastfeeding?

PRP uses the patient’s own blood, but this does not mean elective PRP treatment for hair loss has been adequately studied during pregnancy or breastfeeding.

There are no robust controlled studies establishing the safety and effectiveness of a PRP hair-loss protocol during pregnancy.

Because hair restoration is generally elective, postponing PRP during pregnancy is a reasonable approach.

Breastfeeding decisions may require individualized assessment, including consideration of any anesthetics or other medications used during the procedure.

The absence of a manufactured pharmaceutical drug does not eliminate the need to consider procedural safety and the limitations of available reproductive data.

Is Autologous the Same as Risk Free?

No.

Autologous simply means that the blood comes from the same patient who receives the treatment.

This reduces certain risks associated with the use of donor-derived material.

It does not eliminate complications associated with blood collection, processing, contamination, injection technique, infection, pain or inappropriate patient selection.

Patients should be cautious when a procedure is marketed as completely safe because it uses their own blood.

Natural origin and biological compatibility do not automatically establish safety or clinical effectiveness.

What Happens if PRP Does Not Work?

Not every patient responds to PRP.

After an appropriately performed initial treatment course and a reasonable period for evaluating hair growth, the physician should assess whether meaningful improvement has occurred.

That assessment should ideally include standardized photography, hair counts or other objective measurements obtained before treatment.

If there is no measurable benefit, the diagnosis, preparation protocol, concurrent therapies and overall treatment plan should be reconsidered.

A patient should not automatically be told that additional injections will eventually produce results if they continue treatment.

There is also no validated evidence that increasing platelet concentration, switching to a more expensive commercial system or changing from PRP to PRF will reliably overcome nonresponse.

In some cases, discontinuing PRP and focusing on more established or appropriate treatment options may be the better decision.

The purpose of treatment should be to achieve a meaningful clinical benefit, not to continue an indefinite series of procedures without evidence of improvement.

How Much Should PRP Cost?

The cost of PRP varies substantially depending on geographic location, physician, preparation system and treatment protocol.

PRP for hair loss is generally an elective, out-of-pocket expense.

The total cost can be considerably greater than the price of a single session because many protocols involve an initial treatment series followed by possible maintenance injections.

Price does not establish quality.

A more expensive preparation system is not automatically more effective, and a clinic recommending additional treatments is not necessarily using a better protocol.

Before purchasing a series, patients should understand the cost per session, anticipated total cost, proposed treatment schedule and any expected maintenance fees.

Refund, cancellation and prepaid-package policies should also be disclosed clearly.

Patients should not feel obligated to continue treatment simply because they purchased a discounted series.

Clinical response, rather than financial commitment, should guide decisions about ongoing care.

What Should Someone Ask Before Paying for PRP?

Patients considering PRP should be comfortable asking detailed questions about the treatment being offered.

Important questions include:

• What specific form of hair loss has been diagnosed?
• What clinical evidence supports PRP for my diagnosis?
• What PRP preparation system does the practice use?
• Is the preparation system FDA cleared, and for which intended uses?
• What platelet concentration or approximate total platelet dose does the system produce?
• How is the consistency of the preparation evaluated?
• Is the PRP leukocyte-rich or leukocyte-poor?
• How effectively are red blood cells removed?
• Is the PRP activated before injection?
• What volume will be injected and why?
• How many initial treatments are recommended?
• What evidence supports the proposed treatment frequency?
• How will improvement be measured objectively?
• Will standardized photographs or hair counts be obtained before treatment?
• How long should it take to determine whether treatment is working?
• What happens if there is no measurable response?
• What evidence supports any proposed maintenance schedule?
• Should established medical treatment be continued?
• Who prepares the PRP and who performs the injections?
• What are the possible complications and expected recovery time?
• What is the full anticipated cost, including maintenance?
• If PRF or another platelet concentrate is recommended, what evidence supports that particular preparation?

A qualified treating physician should be able to explain the rationale for the recommended protocol without relying primarily on phrases such as growth factors, stem cell activation, natural regeneration or advanced healing technology.

Patients should be especially cautious when treatment claims are based largely on proprietary equipment, dramatic before-and-after photography or assurances that a particular system produces the highest possible concentration of platelets.

The AHLA Perspective

Platelet-rich plasma occupies an important but frequently misunderstood position in the hair-loss treatment marketplace.

It is no longer scientifically reasonable to dismiss PRP as an unsupported experimental concept. A substantial body of randomized clinical research and several systematic reviews now demonstrate that PRP can improve hair density and certain other hair growth measurements in some patients with androgenetic alopecia.

At the same time, the treatment is often marketed with a degree of certainty that the evidence does not justify.

There is no single standardized PRP product. Platelet concentration, total platelet dose, leukocyte content, red blood cell contamination, activation, injection volume, preparation method and treatment frequency can vary considerably.

That variability matters.

The American Hair Loss Association does not believe that medical practices should advertise PRP as though every preparation is equivalent or that consumers should assume the highest platelet concentration, greatest number of growth factors or most expensive proprietary system will produce the best outcome.

Higher is not automatically better. More treatments are not automatically better treatment.

The strongest clinical evidence currently supports PRP for androgenetic alopecia in men and women. PRP may be used alone in selected patients or as an adjunct to established treatments, but it has not been shown to eliminate the genetic and hormonal processes responsible for progressive pattern hair loss.

Evidence also suggests that combining PRP with topical minoxidil may provide additional benefit in some patients, although the certainty of that evidence remains limited and does not justify recommending combination treatment universally.

PRP does not reliably create new follicles, restore permanently destroyed follicles or permanently reverse advanced baldness.

Its role in alopecia areata remains uncertain, and current guidelines do not support its routine use for that condition. Evidence for scarring alopecia and telogen effluvium is substantially more limited.

The development of platelet-rich fibrin, injectable PRF and concentrated growth-factor preparations is scientifically interesting. Early comparative research suggests that certain formulations may offer advantages under specific study conditions, but these findings should not be translated into broad commercial claims of superiority.

The AHLA also believes that patients deserve transparency about the preparation being administered, the rationale for the recommended protocol, the expected treatment costs and how meaningful improvement will be determined.

There is no justification for repeatedly administering an expensive procedure without a reasonable effort to document whether the patient is benefiting.

The most defensible role for PRP today is as a properly prepared, appropriately administered and objectively monitored treatment for selected patients with a confirmed diagnosis, viable hair follicles and realistic expectations.

The goal should not be to sell a series of injections.

The goal should be to determine whether a particular patient is benefiting from a particular preparation, whether that benefit is clinically meaningful and whether continued treatment is justified.

Selected References

1. Anitua E, Tierno R, Alkhraisat MH. Platelet-Rich Plasma in the Management of Alopecia: A Systematic Review and Meta-Analysis of Clinical Evidence. Dermatol Ther (Heidelb). 2025;15:3213-3252. PubMed

2. Donnelly L, et al. The Role of Platelet-Rich Plasma in Androgenetic Alopecia: A Systematic Review. J Cosmet Dermatol. 2024. PubMed

3. Rodrigues BL, et al. Is Autologous Platelet-Rich Plasma Capable of Increasing Hair Density in Patients With Androgenetic Alopecia? A Systematic Review and Meta-Analysis of Randomized Clinical Trials. An Bras Dermatol. 2024. PubMed

4. Yuan J, He Y, Wan H, Gao Y. Effectiveness of Platelet-Rich Plasma in Treating Female Hair Loss: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Skin Res Technol. 2024;30:e70004. PubMed

5. Umar M, et al. Comparative Efficacy and Safety of Platelet Rich Plasma Versus Topical Minoxidil for Androgenetic Alopecia: A Systematic Review and Meta-Analysis. Aesthetic Plast Surg. 2026;50:1340-1353. PubMed

6. Yao J, Zhu L, Pan M, et al. The Additive Value of Platelet-Rich Plasma to Topical Minoxidil in the Treatment of Androgenetic Alopecia: A Systematic Review and Meta-Analysis. PLOS One. 2024;19:e0308986. PubMed

7. Effect of Platelet Counts and Activator in Platelet-Rich Plasma on the Treatment of Androgenetic Alopecia, Split-Head Comparison: A Randomised, Double-Blind Study. 2023. PubMed

8. Tejapira K, Yongpisarn T, Sakpuwadol N, Suchonwanit P. Platelet-Rich Plasma in Alopecia Areata and Primary Cicatricial Alopecias: A Systematic Review. Front Med. 2022;9:1058431. PubMed

9. Blume-Peytavi U, et al. S3 Guideline Diagnostics and Therapy in Alopecia Areata, Part 2: Therapy, Psychosocial and Cosmetic Support. J Dtsch Dermatol Ges. 2026. Guideline

10. Li M, et al. Comparative Efficacy and Safety of Platelet-Rich Plasma, Injectable Platelet-Rich Fibrin and Concentrated Growth Factors for Female Pattern Hair Loss: A Prospective Multicenter Randomized Clinical Trial. J Dermatolog Treat. 2026. PubMed

11. Sindhusen S, Tawanwongsri W, Eden C. Efficacy of Platelet-Rich Plasma as an Adjunct to Hair Transplantation: A Systematic Review. Cureus. 2025;17:e94116. PubMed

12. Spanish Hair Disorders Group. Recommendations on the Use of Platelet-Rich Plasma in Hair Disorders. Actas Dermosifiliogr. Original Journal

13. U.S. Food and Drug Administration. Microneedling Devices: Regulatory Status, Safety Considerations and Use With Blood Products Including Platelet-Rich Plasma. FDA